The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Designing immunotherapy trials in multiple myeloma: how advocacy groups can work with pharma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses how patient advocacy groups and the pharmaceutical industry can work together to advance patient-centered immunotherapy trials in multiple myeloma. Dr Hansen highlights the importance of incorporating quality of life, treatment burden, access, and biomarker research into trial design, while better representing high-risk and real-world patient populations. She emphasizes that future trials should evaluate the feasibility of clinical implementation to ensure the right patients receive the right treatment at the right time. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
